معرفی
Farida Ahangari, MD, is an Assistant Professor in the Department of Internal Medicine at Yale School of Medicine, with a primary affiliation in the Pulmonary, Critical Care & Sleep Medicine section. She is also associated with the Kaminski Lab and the Center for Precision Pulmonary Medicine (P2MED), where she leads translational research on chronic lung diseases.
- Assistant Professor of Medicine (Pulmonary)
- Department of Internal Medicine, Yale School of Medicine
- Affiliated with Kaminski Lab and P2MED
Education & Training:
- MD, Iran University of Medical Sciences (1995)
- Research Trainee, Queensland Institute of Medical Research (2002)
- Postdoctoral Associate, University at Buffalo (2006)
- Postdoctoral Fellow, Yale School of Medicine (2012)
Research Interests: Dr. Ahangari's research focuses on the pathogenesis of pulmonary fibrosis, particularly the role of metabolic reprogramming and noncoding RNAs (e.g., microRNAs) in disease progression. Her work bridges molecular mechanisms with clinical translation, aiming to develop targeted, cell-specific therapies for idiopathic pulmonary fibrosis (IPF) and other chronic lung diseases.
Publication Trends: Her recent publications emphasize single-cell genomics, epigenetic aging, in silico modeling, and drug discovery in fibrotic lung diseases. Key themes include GPR87 signaling, miR-205 regulation, mitochondrial DNA-TLR9 interactions, and ex vivo fibrosis models, reflecting a strong focus on precision medicine and systems biology.
Scientific Awards:
- Blavatnik Fund for Innovation at Yale
Advising and Grants: While no specific students are listed, Dr. Ahangari leads multicenter collaborative projects and mentors researchers within her lab. She has secured funding from competitive sources such as the Blavatnik Fund, supporting innovative research in pulmonary fibrosis. Her work is highly collaborative, involving frequent co-authorship with Naftali Kaminski, Taylor Adams, Johad Khoury, and others.
Labs and Teams: Dr. Ahangari is an integral member of the Kaminski Lab, a leading research group in pulmonary genomics and fibrosis. She also contributes to the Center for Precision Pulmonary Medicine (P2MED), which leverages advanced technologies to develop personalized treatments for lung diseases.